Clinician’s Guide to Prevention and Treatment of Osteoporosis
Felicia Cosman,S. J. de Beur,Meryl S. LeBoff,E. M. Lewiecki,B. Tanner,S. Randall,Robert Lindsay +6 more
TLDR
The Clinician’s Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteiporosis Foundation in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF.Abstract:
The Clinician’s Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.read more
Citations
More filters
Journal ArticleDOI
The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine.
Nicole C. Wright,Anne C. Looker,Kenneth G. Saag,Jeffrey R. Curtis,Elizabeth Delzell,Susan Randall,Bess Dawson-Hughes +6 more
TL;DR: The goal of this study was to estimate the prevalence of osteoporosis and low bone mass based on bone mineral density (BMD) at the femoral neck and the lumbar spine in adults 50 years and older in the United States, and to note that a substantial number of men and women from other racial/ethnic groups also had osteoporeotic BMD orLow bone mass.
Journal ArticleDOI
An overview and management of osteoporosis
TL;DR: Increasing awareness among doctors, which, in turn, facilitates increase awareness of the normal populace, will be effective in preventing this epidemic of osteoporosis.
Journal ArticleDOI
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
Carolyn D. Runowicz,Corinne R. Leach,N. Lynn Henry,Karen S. Henry,Heather T. Mackey,Rebecca Cowens-Alvarado,Rachel S. Cannady,Mandi Pratt-Chapman,Stephen B. Edge,Linda A. Jacobs,Arti Hurria,Lawrence B. Marks,Samuel J. LaMonte,Ellen Warner,Gary H. Lyman,Patricia A. Ganz +15 more
TL;DR: Recommendations on surveillance for breast cancer recurrence, screening for second primary cancers, assessment and management of physical and psychosocial long-term and late effects of breast cancer and its treatment, health promotion, and care coordination/practice implications are made.
Journal ArticleDOI
A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy
Dora Liu,Alexandra Ahmet,Leanne M Ward,Preetha Krishnamoorthy,Efrem D. Mandelcorn,Richard Leigh,Jacques P. Brown,Albert Cohen,Harold Kim,Harold Kim +9 more
TL;DR: This comprehensive article reviews these adverse events of systemic corticosteroid therapy and provides practical recommendations for their prevention and management based on both current literature and the clinical experience of the authors.
Journal ArticleDOI
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Cynthia A. Stuenkel,Cynthia A. Stuenkel,Susan R. Davis,Anne Gompel,Mary Ann Lumsden,Mary Ann Lumsden,M. Hassan Murad,JoAnn V. Pinkerton,JoAnn V. Pinkerton,Richard J. Santen,Richard J. Santen +10 more
TL;DR: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric and benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause.
References
More filters
Journal ArticleDOI
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
Jacques E. Rossouw,Garnet L. Anderson,Ross L. Prentice,Andrea Z. LaCroix,Charles Kooperberg,Marcia L. Stefanick,Rebecca D. Jackson,Shirley A.A. Beresford,Barbara V. Howard,Karen C. Johnson,Jane Morley Kotchen,Judith K. Ockene +11 more
TL;DR: Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
Journal ArticleDOI
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial
Garnet L. Anderson,Marian C. Limacher,Annlouise R. Assaf,Tamsen Bassford,Shirley A.A. Beresford,Henry R. Black,Denise E. Bonds,Robert L. Brunner,Robert G. Brzyski,Bette J. Caan,Rowan T. Chlebowski,J. David Curb,Margery Gass,Jennifer Hays,Gerardo Heiss,Susan L. Hendrix,Barbara V. Howard,Judith Hsia,F. Allan Hubbell,Rebecca D. Jackson,Karen C. Johnson,Howard L. Judd,Jane Morley Kotchen,Lewis H. Kuller,Andrea Z. LaCroix,Dorothy S. Lane,Robert Langer,Norman L. Lasser,Cora E. Lewis,JoAnn E. Manson,Karen L. Margolis,Judith K. Ockene,Mary Jo O'Sullivan,Lawrence S. Phillips,Ross L. Prentice,Cheryl Ritenbaugh,John A Robbins,Jacques E. Rossouw,Gloria E. Sarto,Marcia L. Stefanick,Linda Van Horn,Jean Wactawski-Wende,Robert B. Wallace,Sylvia Wassertheil-Smoller +43 more
TL;DR: The use of conjugated equine estrogen (CEE) increases the risk of stroke, decreases therisk of hip fracture, and does not affect CHD incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years, indicating no overall benefit.
Journal ArticleDOI
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Robert M. Neer,Claude D. Arnaud,Jose R. Zanchetta,Richard L. Prince,Gregory A Gaich,Jean-Yves Reginster,Anthony B. Hodsman,Erik Fink Eriksen,Sophia Ish-Shalom,Harry K. Genant,Ouhong Wang,Bruce H. Mitlak +11 more
TL;DR: Treatment of postmenopausal osteoporosis with parathyroid hormone decreases the risk of vertebral and nonvertebral fractures; increases vertebral, femoral, and total-body bone mineral density; and is well tolerated.
Journal ArticleDOI
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Dennis M. Black,Steven R. Cummings,David B. Karpf,Jane A. Cauley,Desmond E. Thompson,Michael C. Nevitt,Douglas C. Bauer,Harry K. Genant,William L. Haskell,Robert Marcus,Susan M. Ott,James C. Torner,Sara A. Quandt,Theodore F. Reiss,Kristine E. Ensrud +14 more
TL;DR: Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures.
Journal ArticleDOI
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.
RT Burge,RT Burge,Bess Dawson-Hughes,Daniel H. Solomon,John B. Wong,King Ab,Anna N. A. Tosteson +6 more
TL;DR: This study predicts the burden of incident osteoporosis‐related fractures and costs in the United States, by sex, age group, race/ethnicity, and fracture type, from 2005 to 2025.
Related Papers (5)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black,Pierre D. Delmas,Richard Eastell,Ian R. Reid,Steven Boonen,Jane A. Cauley,Felicia Cosman,Peter L. Lakatos,Ping Chung Leung,Z. Man,Carlos Mautalen,Peter Mesenbrink,Huilin Hu,John Caminis,Karen Tong,Theresa Rosario-Jansen,Joel S. Krasnow,Trisha F. Hue,Deborah E. Sellmeyer,Erik Fink Eriksen,Steven R. Cummings +20 more